Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q1 FY27 Earnings Presentation
29 slides from Vimta Labs's earnings presentation, Jul 20, 2026
Slide 1: SUJANI VASIREDDI Date:
Digitally signed by SUJANI SUJANI VASIREDDI VASIREDDI Date: 2026.07.20 15:15:23 +05'30'
Slide 2: Investor Presentation Q1 FY27
INVESTOR PRESENTATION Q1 FY27 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table Of Contents
Table Of • Q1 FY27 Earnings Contents • Company Overview • Industry Landscape • Our Competitive Advantage • Way Forward 3
Slide 5: Q1 FY27 Earnings
Q1 FY27 Earnings Section • Q1 FY27 Highlights 01 • • Key Metrics: Q1 FY27 Profit & Loss Statement • Financial Track Record 4
Slide 6: Q1 FY27 Highlights
Q1 FY27 Highlights Rs 1,129 Mn Rs 411 Mn Rs 283 Mn Margin 36.4% Total Income EBITDA PBT Rs 4.7 Rs 180 Mn Rs 210 Mn Margin 18.6% CAPEX (Cash EPS PAT Outflow) 5
Slide 7: Key Metrics: Q1 FY27
Key Metrics: Q1 FY27 Total Income EBIDTA & EBIDTA PAT & PAT Margin Basic EPS (In ₹) (In ₹ Mn) Margin (In ₹ Mn, %) (In ₹ Mn, %) EBIDTA EBIDTA Margin PAT PAT Margin 13.7% 16.0% 11.1% 5 YoY YoY YoY 35.7% 37.6% 19.0% 18.9% 36.4% 18.6% 993 1,120 1,129 354 421 411 189 211 210 4.2 4.7 4.7 0 Q1FY26 Q4FY26 Q
Slide 8: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q1 FY27 Q4 FY26 QoQ(%) Q1 FY26 YoY (%) Revenue from Operations 1,091 1,092 976 Other Income 38 28 17 Total Income 1,129 1,120 0.8% 993 13.7% Material and Testing Costs 226 224 188 Cost of lab setup 0 0 0 Changes in inventories of work-in-progress - - - Empl
Slide 9: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA PAT & PAT Margin Margin 19% 36% 36% 36% 19% 19% 31% 33% 17% 29% 15% 15% 10.5% 16.2% 17.0% CAGR CAGR CAGR (FY22-FY26) (FY22-FY26) 2,797 3,216 2,923 3,482 4,163 1,129 (FY22-FY26) 817 984 977 1,262 1,489 411 413 482 488 668
Slide 10: Company Overview
Company Overview Section • Vimta at a Glance 02 • • Our Journey Our Offerings • Geographical Presence • Management 9
Slide 11: Vimta at a Glance
Vimta at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high-quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, sma
Slide 12: Our Journey
Our Journey Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & development 2024 ~600,000 ft2 1300+ 492 M services; Food; Environment; Electronics Testing 3,223 M Analytical – Pharma, Biopharma & Food; Clinical 2015 400,000+ ft2 1000+ 580 M Research; Preclinical; C
Slide 13: Our offerings
Our offerings Drug discovery and development services Food, Agri & Environmental Testing Electronics & Electricals Testing 12
Slide 14: Drug discovery and development services
1. Drug discovery and development services Offerings Pharma Analytical Clinical Research Preclinical Research Pharmaceuticals, Biologics, Medical Industry Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health Device, Agrochemical, Speciality Chemicals Accreditations & DCA, USFDA
Slide 15: Biologics - Contract Research & Development Services
2. Biologics - Contract Research & Development Services Offerings Process Development Product Development Industry Biotech & Biopharma Requirements & Small scale Non GMP (R&D) ICH Guidelines (Q2, Q6B, etc.) Compliant guidelines Process and Product Development – DS & DP o Cell Line Development o Down
Slide 16: Food, Agri & Environmental Testing
3. Food, Agri & Environmental Testing Industry Food Manufacturing & Processing industries, Cultivation, Export, Retail, Nutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed and environmental testing services for various industries viz., Oil & Gas, Power, Cement, Mining, Infrastructure, etc
Slide 17: Electricals & Electronics Testing & Certification
4. Electricals & Electronics Testing & Certification Industry Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries No. of Locations 2 (Hyderabad) Accredit
Slide 18: Geographical Presence
Geographical Presence Food & Pharma Environment Electrical and Electronics Hyderabad Hyderabad Hyderabad Ahmedabad Noida Mumbai (NFL) Nashik Bengaluru Nellore Kolkata Pharma Electronics & Electrical Hyderabad (Headquarters) Food & Environment 17
Slide 19: Key Management Team
Key Management Team Harriman Vungal S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Siva Kambhampati Executive Director - Executive Chairman Managing Director Executive Director Chief Financial Officer Operations • Dr. S P Vasireddi is a Scientist – • Harita has close to 3 decades • Sreenivas’s
Slide 20: Industry Landscape
Industry Landscape Section • Market Opportunity 03 • Factors Driving Industry Growth 19
Slide 21: Markets Opportunity (Global)
Markets Opportunity (Global) Pharmaceutical Electronics Preclinical Food Testing Analytical Testing Testing 15,700 5,500 48,000 25,581 (USD Mn) 10,500 3,700 Global 26,300 17,962 2026 | 2031 2026 | 2031 2025 | 2033 2025 | 2033 20
Slide 22: Markets Opportunity (Indian)
Markets Opportunity (Indian) Pharmaceutical Electronics Preclinical Food Testing Analytical Testing Testing 780 451 1,510 15,300 (USD Mn) Indian 368 215 718 9,190 2025 | 2035 2025 | 2033 2025 | 2033 2025 | 2035 21
Slide 23: Factors Driving Industry Growth
Factors Driving Industry Growth • Industry moving towards complex generics and Biosimilars • Surge in demand for certification services of electrical & electronic • Increasing demand and Govt. push for products, growing defence budgets new drug innovations, growth in and make in India initiatives bi
Slide 24: Our Competitive Advantage
Our Competitive Advantage Section • Our Position in the CRTO Landscape 04 • Our Strength 23
Slide 25: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical Clinical Research Electronics & Electricals • #1 in India • Among the most reputed CROs in • One of the leading labs in • Customers – 90% of India top 20 India Southern India • 40% revenues from overseas • 75% of revenues from overseas Food & Envi
Slide 26: Our Strengths
Our Strengths Infrastructure Innovations Knowledge Unparalleled lab Continuous addition Multi-disciplinary, infrastructure in the of services and skilled and trained country. Gold LEED evolving excellence manpower certified Vivarium Facilities with scalable capacities Customer Centricity Compliance
Slide 27: Way Forward
Way Forward Section • Our Key Growth Drivers & Strategies 05 26
Slide 28: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable Core business Core operational Best markets strategies strategies practices Growth momentum Capacity expansions Operational excellence Good corporate governance in markets Service innovations Hiring right talent Risk management Growing d
Slide 29: Thank You
THANK YOU Vimta Labs Ltd. Registered Office Siva Kambhampati | Chief Financial Officer #142, IDA Phase 2, Cherlapally, Siva.Kambhampati@vimta.com Hyderabad Telangana, India. 500051 Ernst & Young Siddesh Chawan Advait Bhadekar NSE: VIMTALABS ISIN: INE579C01029 Siddesh.Chawan@in.ey.com Advait.Bhadekar